STAGE III RENAL CELL CANCER AJCC V8

This study tests a personalized vaccine made from a patient's own tumor proteins, combined with the immunotherapy drug pembrolizumab, for people with advanced solid tumors. The goal is to see if this combination is safe and helps the immune system fight cancer more effectively. A…

This study tests whether a combination of three drugs—bevacizumab, erlotinib, and atezolizumab—can shrink or stabilize advanced kidney cancer in people with a rare inherited form (HLRCC) or sporadic papillary kidney cancer. The drugs work by cutting off the tumor's blood supply, …

This early-phase study tests whether adding a live bacteria product (EXL01) to standard immunotherapy (nivolumab + ipilimumab) is safe and helps control metastatic kidney cancer. About 33 adults with advanced renal cell carcinoma will receive either the standard drugs alone or wi…

This early-phase study tests a wearable device that creates low-intensity electric fields (tumor treating fields) combined with either cabozantinib or a chemo-immunotherapy pair (nab-paclitaxel and atezolizumab) in people with advanced solid tumors in the abdomen or chest. The go…

This study is for people with advanced kidney cancer that has spread and cannot be removed by surgery. It tests whether adding a precise, high-dose form of radiation (SABR) to the main tumor, alongside standard immunotherapy drugs, can better control the cancer and delay its grow…

This study tests whether adding inulin gel, a common fiber supplement, to standard immunotherapy drugs (ipilimumab and nivolumab) can help control advanced kidney cancer. About 55 adults with cancer that has spread or is locally advanced will receive the combination. The goal is …

This study looks at whether getting immunotherapy in the morning or afternoon changes how well it fights advanced or metastatic solid tumors. Researchers believe the body's internal clock (circadian rhythm) might affect immune response. About 160 adults with certain cancers like …

This study looks at whether giving the cancer drug nivolumab as a shot at home is as good as getting it at the clinic. About 50 adults with various cancers will try both ways to see which they prefer and how it affects their quality of life. The goal is to reduce the time, cost, …

This study collects tissue samples from people with various advanced or early-stage cancers to train a new diagnostic platform called Elephas. The goal is to see how accurately it can predict whether a patient will respond to immunotherapy or chemoimmunotherapy. About 324 partici…